Literature DB >> 29889113

The role of appendectomy at the time of laparoscopic surgery for benign gynecologic conditions.

Ann Peters1, Suketu M Mansuria.   

Abstract

PURPOSE OF REVIEW: The risk-benefit ratio of concurrent appendectomy at the time of gynecologic surgery has long been debated and remains controversial. However, emerging data on the appendix's role in chronic pain syndromes point to a previously unrecognized link between gynecologic disorders and appendicular pathology. In this article, we review the indications for appendectomy at the time of laparoscopic gynecologic surgery for the treatment of endometriosis and chronic pelvic pain. RECENT
FINDINGS: The incidence of appendiceal endometriosis is highly variable depending on the patient population selected. Although rare in patients undergoing appendectomy for acute appendicitis, women with endometriosis may experience rates as high as 9.3-39.0%, especially when suffering from deep infiltrative endometriosis. Appendectomy may also significantly reduce pain in women with unexplained chronic pelvic pain.
SUMMARY: Despite lack of prospective data, retrospective studies suggest that appendectomy during gynecologic procedures for chronic pelvic pain and severe endometriosis may be beneficial and necessary to fully address the treatment of these complex gynecologic conditions. In these clinical scenarios, the benefits of laparoscopic appendectomy at the time of the primary gynecologic procedure may outweigh the risks and cost, and should be discussed with patients preoperatively.

Entities:  

Mesh:

Year:  2018        PMID: 29889113     DOI: 10.1097/GCO.0000000000000466

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  1 in total

1.  Histopathological features of incidental appendectomy specimens obtained from living liver donors.

Authors:  Sami Akbulut; Cemalettin Koç; Barış Sarıcı; Mehmet Özcan; Emine Şamdancı; Sezai Yılmaz
Journal:  Turk J Gastroenterol       Date:  2020-03       Impact factor: 1.852

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.